DD is key and is your responsibility. Just my opinions here
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fed is committed to 2% inflation. Housing inflation price needs a strong correction.
#DontFightTheFED #Affordablehomesforthepeople
My position was down 35 % on this one. Just bought a bit more.
SHORTS HAVE TO GET THE 3 ON THEIR OWN.
1000$$$ GTC ORDER AND YOUR SHARES ARE NOT AVAILIABLE FOR SELL??
GME MOASS
GME THAT BOOTY
Try to buy and hold, if you need to sell then sell.
#haveaniceday
#reformthehouse
#darkpoolcheckers
#lilguy
#apes
#tribe
EYEBALLS
AND JUST LIKE THAT STONKY IS RUNNING....
So a reverse split before major consturction costs?
not good ima thinkin.
[url][/https://www.urotoday.com/conference-highlights/2022-annual-meeting/aua-2022-bladder-caner/137101-aua-2022-final-clinical-results-of-pivotal-trial-of-il-15r-alpha-fc-superagonist-n-803-with-bcg-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-nmibc-cis-and-papillary-cohorts?mtm_campaign=Chamie_SocialAUA22_ID137101url][tag]Final Clinical Results of Pivotal Trial of IL-15R&[alpha]Fc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) CIS and Papillary Cohorts/tag]
trade 19112 nsad 16;00;01 271,005 share buy
Big money moving in on the down low...
BULLISH
Expect analyst updates AFTER MORE LIKE 19112.
Bullish activity.
back to double digits soon .... JMO
trade 19112 nsad 16;00;01 271,005 share buy
Big money moving in on the down low...
BULLISH
Expect analyst updates AFTER MORE LIKE 19112.
Bullish activity.
back to double digits soon .... JMO
accumulation.
Good afternoon.
$TLTFF - receives a target raise from Research Capital
Published on April 5, 2022
New interim clinical data has Research Capital Corporation analyst Andr Uddin feeling more bullish about Canadian drug developer Theralase Technologies (Theralase Technologies Stock Quote, Charts, News, Analysts, Financials TSXV:TLT). Uddin maintained a “Speculative Buy” rating while raising his target price from $0.70/share to $1.20/share for a projected return of 161 per cent in an update to clients on Tuesday.
Theralase Technologies receives a target raise from Research Capital (cantechletter.com/)
$TLTFF - receives a target raise from Research Capital
Published on April 5, 2022
New interim clinical data has Research Capital Corporation analyst Andr Uddin feeling more bullish about Canadian drug developer Theralase Technologies (Theralase Technologies Stock Quote, Charts, News, Analysts, Financials TSXV:TLT). Uddin maintained a “Speculative Buy” rating while raising his target price from $0.70/share to $1.20/share for a projected return of 161 per cent in an update to clients on Tuesday.
Theralase Technologies receives a target raise from Research Capital (cantechletter.com/)
Theralase Technologies receives a target raise from Research-Capital
123414 Still long TLTFF.
The 67% CR@ 18/24 months is unmatched.
Those full dose patients are becoming dominate in the study.
Under-treaded patients are still in the mix but getting reduced.
AND... Now the kicker... the undertreated patients were not treated in the protocol of the study.
Read what the analysis says about all the one dose patients.
TLTFF on track and still solid as heck.
That's why that analyists moved his rating to .95usd / 1.20cad
He nailed it before.
Stay tuned sports fan the race is just heating up.
Theralase Technologies receives a target raise from Research-Capital
https://www.cantechletter.com/2022/04/theralase-technologies-receives-a-target-raise-from-research-capital/
Theralase Technologies receives a target raise from Research-Capital
123414 Still long TLTFF.
The 67% CR@ 18/24 months is unmatched.
Those full dose patients are becoming dominate in the study.
Under-treaded patients are still in the mix but getting reduced.
AND... Now the kicker... the undertreated patients were not treated in the protocol of the study.
Read what the analysis says about all the one dose patients.
TLTFF on track and still solid as heck.
That's why that analyists moved his rating to .95usd / 1.20cad
He nailed it before.
Stay tuned sports fan the race is just heating up.
Theralase Technologies receives a target raise from Research-Capital
https://www.cantechletter.com/2022/04/theralase-technologies-receives-a-target-raise-from-research-capital/
The comp hit 67% CR at 18/24months on one dose ph 1
FDA issued BTD AA Priority review from that data.
Then the first 12 patients were undertreated.
Now full dose data is becoming dominant in study
and in the NMIBC Nonresponse market.
This recent article from UroToday (01 April) reveals that the 2 year CR rate for N-803 is around 36%:
"In Cohort A, complete response was noted in 59 of 83 (71%) at the primary endpoint designated 3- or 6-month time point. Impressively, more than half (52%) had durable response out to 2 years or beyond."
52% of 59 = 30 out of 83 patients = 36%
This jives with Immunity Bio's announcement of their results in February:
"Indeed, the benchmark of 30% durable response at 18 to 24 months for a clinically meaningful therapy “is likely too high and may not be realistically achievable,”3 according to recommendations published in the Journal of Clinical Oncology. This “realistically unachievable” endpoint of 30% durable response at 18 months has in fact now been achieved and exceeded with the combination of Anktiva and BCG in this trial reported today. "
According to the list at the bottom of the following article TLD1433 is one of 14 trials currently going on in this space.
The full Doses are now becoming dominant in the study.
The first ph2 12 patients who were under treated in the first dose negativly affected the CR rates.
Now the full dose patients are starting to show up at the data points.
It's gonna be good.
SEC violation
1 april 2022
TLTFF TRADE 10 -11:32am 43s
TLTFF TRADE 11 11:33am 58s
RE 10 @ 3704
RE 10 @ 3726
Exucuted Trades not recorded on 1 min chart
SEC violation???
I
SEC violation
1 april 2022
TLTFF TRADE 10 -11:32am 43s
TLTFF TRADE 11 11:33am 58s
RE 10 @ 3704
RE 10 @ 3726
Exucuted Trades not recorded on 1 min chart
SEC violation???
I
Check out the run SESN and IBRX had when they
thougtht they were
the gold standard for NMIBC nonresposne.. TLTFF
TLTFF as per FDA in in progress with BTD and AA
Priority review may be completed now.
$TLTFF Strength to the long hands.
When the stock below .40 are finished up.. then what?
blue sky??
TLTFF Long on the strong science and market confirmation of NMIBC leader.
Strong chart for a reason! The data.
ORF PHAC ST MICHAELS
TIMELY AND FRINDLY
MEETING NEW FRIENDS..
Brewing coffee..
in a skillet..
therefore INCREASING THE STRICK PRICE
WARRANTS TRADE IN OPEN MARKET
Their burn rate is slow they are good for about a year.
LAST NINE MONTH BUR N RATE WAS .375mil PER QUARTER!
$TLTFF 07 .14 .28 .35 What's next in your pattern?
$TLTFF
12OCT20 TO PRESENT .076-.3775
$IBRX
12OCT20 TO PRESENT 8.38 - 6.18
$SESN
12OCT20 TO PRESENT 1.09 - .5811 .
07 .14 .28 .35 What's next in your pattern?
$TLTFF 07 .14 .28 .35 What's next in your pattern?
$TLTFF
12OCT20 TO PRESENT .076-.3775
$IBRX
12OCT20 TO PRESENT 8.38 - 6.18
$SESN
12OCT20 TO PRESENT 1.09 - .5811 .
07 .14 .28 .35 What's next in your pattern?
$TLTFF 07 .14 .28 .35 What's next in your pattern?
$TLTFF
12OCT20 TO PRESENT .076-.3775
$IBRX
12OCT20 TO PRESENT 8.38 - 6.18
$SESN
12OCT20 TO PRESENT 1.09 - .5811 .
07 .14 .28 .35 What's next in your pattern?
$TLTFF Consolidating into uptrend! The best CR rates!!!
And the FDA know it. that's why the BTD and AA are in play now.
They are not making pot brownies here.
When in doubt zoom out..
Look to the big picture.
Solid science solid results
No smoke and mirror numbers.
$TLTFF Consolidating into uptrend! The best CR rates!!!
And the FDA know it. that's why the BTD and AA are in play now.
They are not making pot brownies here.
When in doubt zoom out..
Look to the big picture.
Solid science solid results
No smoke and mirror numbers.
$TLTFF Consolidating into uptrend! The best CR rates!!!
And the FDA know it. that's why the BTD and AA are in play now.
They are not making pot brownies here.
When in doubt zoom out..
Look to the big picture.
Solid science solid results
No smoke and mirror numbers.
$TLTFF SOLID SCIENCE AND SOLID RESULTS! UPDATES SOON.
These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.
$TLTFF SOLID SCIENCE AND SOLID RESULTS! UPDATES SOON.
These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.
That was just steady all day accumulation.
Perhaps the market wants 2b having this stock? TLTFF
Who's PIVOTAL PH2B NMIBC NONRESPONSE FDA DARLING?!?!?!?!?!
Almost like the FDA was saying 2b or not 2b...
call me call me anytime call me..
No new patient updates since nov 29 2021.
Puppies love chillidogs!
When Theral-ACES HIGH hits the next gears..
We hear about it after they have talked with the FDA.. YES???
Go check it out .... maybe im wrong?? naw... i don't think so....
vroom vroom...
TLTFF LONG AND STRONG ON SOLID SCIENCE!!!
If Theralase has toppling data current/material news. The may take that data to date to the FDA. Sometime Theralase cannot report due to regulatory restrictions.
Competitors will know this and report during the assessment period trying to inspire impatience.
Here is why I am considering this scenario...
They normally report
Cancer research updates and Cutting edge covid research updates in the quarterly.
However this time around they have PR the covid research
Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
Toronto, Ontario – February 7, 2022
Ok then look to the insider buying...
The Corporate presentation is of no interest to the FDA.
The Company newsletter is of no interest to the FDA.
The FDA is interested in the data to date.
May 19, 2020Shawn Shirazi went on to say, "In a 3Q2019 conference call with the FDA, it was discussed and agreed between the FDA and the Company,
post receipt of the FDA IND authorization, based on the clinical study data collected to date.
It was further discussed and agreed that Theralase would potentially be eligible for Breakthrough Therapy Designation ("BTD") and/or Accelerated Approval (AA)
if Theralase can demonstrate clinically significant results (high safety profile and high efficacy response), similar to the safety and efficacy results observed in the Phase Ib NMIBC study (high safety profile and 67% CR) at an interim analysis of approximately 20 to 25 patients enrolled and successfully treated."
This is the link to the quarterly newsletters... Currently the public only has information on this study up to NOV 28 2021.
Link to TLTFF NEWSLETTERS
TLTFF long.
$TLTFF Darling... CAN WE JUST TALK??.. CAN WE JUST TALK??
THINK ABOUT WHERE XRAY IS GOING??
Theralase® Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds March 4, 2019
I just found it interesting back when they released the above release that they included bladder cancer.
Back in the day they were publishing info on solid tumor work.
New lab and they are getting things done for sure!
Did ya'll see that fund mangers face when they were asking Shawn if lil ol therylase could get to standard of care for NMIBC...hahhahhhha golden moment...hhshshshshshs
Shawn stonewalled them alll....hahahhahahaha
Cool a$$ a freakin ice cube baby.... hahahahha
Shawn knows....
Hey... check into patient 4 from study one.. yeah dig into that about the rules the FDA had to change/clarify/set up for this study. Yeah Theralse almost hit 100 percent there...
Bullish baby bullish... Let's go!
TLTFF the science is strong in this one!
Look to the cost expense/number of treatments for alternatives. BCG is in short supplly. A treatment like that using scare resources will always be expensive.
.
Alternative treatments are very cost prohibative
and will have a very very very difficult time competing with Theralase.
JMO Time for a coffee.
While others are giving their numbers a nice massage.
Theralase dialed things back on this freakin beast for cation then after they let the kids drive the care with dad well they are ready to drive it for themselfs..... YES Baby YES.....
Full doses and full throttle!!
TLTFF for NMIBC NONRESPONSE!!